Øivind Torkildsen er professor i nevrologi ved Universitetet i Bergen og overlege ved nevrologisk avdeling, Haukeland Universitetssykehus. Han er seksjonsleder for seksjon for nevrologi ved Universitetet i Bergen.

Han forsker på multippel sklerose (MS) og arbeider særlig med behandlingsstudier på sykdommen. 

Han er koordinator for EBV-MS prosjektet, som har finansiering fra Horizon (Overview of all EBV-MS project partners | EBV-MS | UiB). 

Vitenskapelig artikkel

• Lisa G. Schoof; Brit Ellen Rød; Sahla El Mahdaoui et al. (2025). Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)—an individual participant data meta-analysis. (ekstern lenke)
• Jeremy Hobart; Amy Bowen; George Pepper et al. (2018). International consensus on quality standards for brain health-focused care in multiple sclerosis. (ekstern lenke)
• Trygve Holmøy; Qin Ying Esbensen; Øivind Torkildsen et al. (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study.. (ekstern lenke)
• Frank Riemer; Ellen Skorve; Ofer Pasternak et al. (2023). Microstructural changes precede depression in patients with relapsing-remitting Multiple Sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Christian A. Vedeler; Elling Ulvestad et al. (2005). High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. (ekstern lenke)
• O Torkildsen; Øivind Fredvik Torkildsen; Egil Utsi et al. (2005). Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. (ekstern lenke)
• Eystein Oveland; Agnes Elisabeth Nystad; Frode Berven et al. (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. (ekstern lenke)
• Ann Cathrine Kroksveen; Jacob D. Jaffe; Elise Aasebø et al. (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Øystein Alexander Power; Anette Storstein (2016). Detection of varicella-zoster virus DNA during medullary and brainstem relapses in multiple sclerosis. (ekstern lenke)
• Brage Brakedal; Irene Hana Flønes; Simone B. C. Frizell Reiter et al. (2017). Glitazone use associated with reduced risk of Parkinson's disease. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Lars Bø (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. (ekstern lenke)
• Brit Ellen Rød; Einar August Høgestøl; Øivind Torkildsen et al. (2025). Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation. (ekstern lenke)
• Jette Lautrup Frederiksen; Luca Massacesi; Helle Hvilsted Nielsen et al. (2024). Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence study. (ekstern lenke)
• Øivind Fredvik Grytten Torkildsen; Alla Nikolajevna S Bru; Gry Inger N Behzadi et al. (2026). Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. (ekstern lenke)
• Ragnhild Reehorst Lereim; Eystein Oveland; Y. Xiao et al. (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. (ekstern lenke)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2019). Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. (ekstern lenke)
• Øivind Fredvik Torkildsen; Per Knappskog; Harald Inge Nyland et al. (2008). Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. (ekstern lenke)
• Ellen Skorve; Astri Lundervold; Øivind Torkildsen et al. (2019). The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). (ekstern lenke)
• Sveinung Fjær; Lars Bø; Kjell-Morten Myhr et al. (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. (ekstern lenke)
• Tomas Kalincik; Sifat Sharmin; Izanne Roos et al. (2024). Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Kristin Ingeleiv Løken-Amsrud; Stig Wergeland et al. (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. (ekstern lenke)
• Jens Kuhle; G Disanto; R Dobson et al. (2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. (ekstern lenke)
• Grethe Åstrøm Ueland; Hans Olav Ueland; Ann-Elin Meling Stokland et al. (2023). Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease. (ekstern lenke)
• Øivind Fredvik Torkildsen; Harald Inge Nyland; Helge Myrmel et al. (2008). Epstein-Barr virus reactivation and multiple sclerosis. (ekstern lenke)
• E. Coerver; L. Schoof; L. Hogenboom et al. (2024). The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. (ekstern lenke)
• Sveinung Fjær; Lars Bø; Arvid Lundervold et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. (ekstern lenke)
• Silje Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2016). No association of tobacco use and disease activity in multiple sclerosis. (ekstern lenke)
• Stig Wergeland; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. (ekstern lenke)
• Brit Ellen Rød; Øivind Torkildsen; Kjell-Morten Myhr et al. (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Brunborg; Anne Marita Milde et al. (2009). A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. (ekstern lenke)
• Ingrid Anne Lie; Kristin Wesnes; Silje Agnethe Stokke Kvistad et al. (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Kjell-Morten Myhr; Nina Agnethe Grytten; Øivind Torkildsen et al. (2012). A need for national registries and international collaborative research in multiple sclerosis. (ekstern lenke)
• Liv Furevik; Oksana Lapina; Elisabeth Margrete Stokke Lindland et al. (2025). Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2024). Migraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women. (ekstern lenke)
• Yichuan Xiao; Jin Jin; Mikyoung Chang et al. (2013). Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. (ekstern lenke)
• Kristin Nielsen Varhaug; Christian Barro; Kjetil Lauvland Bjørnevik et al. (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). The cuprizone model: regional heterogeneity of pathology. (ekstern lenke)
• Øivind Fredvik Torkildsen; Jan Harald Aarseth; Espen Benjaminsen et al. (2014). Month of birth and risk of multiple sclerosis: confounding and adjustments. (ekstern lenke)
• Egil Rørvik Røsjø; Kjell-Morten Myhr; Kristin Ingeleiv Løken-Amsrud et al. (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. (ekstern lenke)
• Agnes Elisabeth Nystad; Stig Wergeland; Lage Aksnes et al. (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Brunborg; Frits Alan Thorsen et al. (2009). Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. (ekstern lenke)
• Stig Wergeland; Anagha P Parkar; Snezana Maric et al. (2021). En ung kvinne med langvarig kvalme, oppkast og hikke. (ekstern lenke)
• Hilde Marie Torgauten; Therese Bredholt Onyango; Sonja Ljostveit et al. (2024). Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (ekstern lenke)
• Kjetil Lauvland Bjørnevik; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.. (ekstern lenke)
• Agnes Elisabeth Nystad; Ragnhild Reehorst Lereim; Stig Wergeland et al. (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. (ekstern lenke)
• Trond Trætteberg Serkland; Silje Skrede; Erik Ingmar Hallin et al. (2025). Pharmacokinetic-pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval. (ekstern lenke)
• Hilde Marie Torgauten; Kjell-Morten Myhr; Stig Wergeland et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (ekstern lenke)
• Maria Ban; Stacy Caillier; Inger-Lise Mero et al. (2013). No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. (ekstern lenke)
• Margitta Theodora Kampman; Jan Harald Aarseth; Nina Agnethe Grytten et al. (2013). Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. (ekstern lenke)
• Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Kjell-Morten Myhr et al. (2008). The cuprizone model for demyelination. (ekstern lenke)
• Maria Therese Fossum; Hilde Marie Torgauten; Jan Harald Aarseth et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety. (ekstern lenke)
• Silje Agnethe Stokke; Anne Kristine Lehmann; Linn Trovik et al. (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. (ekstern lenke)
• Ingrid Anne Lie; Sezgi Kacar; Kristin Wesnes et al. (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. (ekstern lenke)
• Ellen Skorve; Astri Lundervold; Øivind Torkildsen et al. (2020). A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. (ekstern lenke)
• Øivind Fredvik Torkildsen; Christine Stansberg; Solveig Mjelstad Angelskår et al. (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen; Kjell-Morten Myhr (2017). An update on cladribine for relapsing-remitting multiple sclerosis. (ekstern lenke)
• Shamundeeswari Anandan; Karina Maciak; Regina Breinbauer et al. (2025). In-Depth Characterization of L1CAM+ Extracellular Vesicles as Potential Biomarkers for Anti-CD20 Therapy Response in Relapsing–Remitting Multiple Sclerosis. (ekstern lenke)
• Max Korbmacher; Ingrid Anne Lie; Kristin Wesnes et al. (2025). Multimodal predictors of disability progression and processing speed decline in relapsing–remitting multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Nina Agnethe Grytten; Jan Harald Aarseth et al. (2012). Month of birth as a risk factor for multiple sclerosis: an update. (ekstern lenke)
• Kristin Ingeleiv Løken; Kjell-Morten Myhr; Jacob Bakke et al. (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. (ekstern lenke)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2021). Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. (ekstern lenke)
• Katharina Natalie Gottschlich; Zinajda Zolic-Karlsson; Eline Aas et al. (2024). Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis. (ekstern lenke)
• Karine Eid; Øivind Fredvik Grytten Torkildsen; Jan Harald Aarseth et al. (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Association of adverse childhood experiences with the development of multiple sclerosis. (ekstern lenke)
• Christopher Elnan Kvistad; Øivind Torkildsen; Halvor Næss et al. (2016). Trombolytisk behandling og trombektomi ved ukjent slagdebut. (ekstern lenke)
• Karine Eid; Øivind Torkildsen; Jan Harald Aarseth et al. (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. (ekstern lenke)
• Egil Rørvik Røsjø; Peter Andreas Vold Lossius; Nada Abdelmagid et al. (2017). Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. (ekstern lenke)
• Jan-Lukas Førde; Lars Herfindal; Kjell-Morten Myhr et al. (2023). Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro. (ekstern lenke)
• Jill Anette Opsahl; Marc Vaudel; Astrid Guldbrandsen et al. (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. (ekstern lenke)
• Brit Ellen Rød; Stig Wergeland; Kjetil Lauvland Bjørnevik et al. (2023). Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. (ekstern lenke)
• Kjell-Morten Myhr; Øivind Fredvik Torkildsen (2020). Serum NFL levels should be used to monitor multiple sclerosis evolution - No.. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Peter Andreas Vold Lossius; Øivind Torkildsen et al. (2015). Miljøets betydning ved multippel sklerose. (ekstern lenke)
• Christopher Elnan Kvistad; Anne Kristine Lehmann; Silje Agnethe Stokke et al. (2024). Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway. (ekstern lenke)
• Øivind Fredvik Torkildsen; Kjell-Morten Myhr; Vegard Skogen et al. (2020). Tenofovir as a treatment option for multiple sclerosis. (ekstern lenke)
• Tomas Kalincik; Sifat Sharmin; Izanne Roos et al. (2023). Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Nina Agnethe Grytten; Øivind Torkildsen; Jan Harald Aarseth et al. (2013). Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. (ekstern lenke)
• Kjetil Bjørnevik; Trond Riise; Espen Benjaminsen et al. (2017). Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. (ekstern lenke)
• Ann Cathrine Kroksveen; Astrid Guldbrandsen; Marc Vaudel et al. (2017). In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. (ekstern lenke)
• Hanne Marie Lunde; Øivind Torkildsen; Lars Bø et al. (2016). Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. (ekstern lenke)
• Ann Cathrine Kroksveen; Jill Anette Opsahl; Astrid Guldbrandsen et al. (2015). Cerebrospinal fluid proteomics in multiple sclerosis. (ekstern lenke)
• Kristin Wesnes; Kjell-Morten Myhr; Trond Riise et al. (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen (2016). Familieplanlegging, graviditet og amming ved multippel sklerose. (ekstern lenke)
• Silje Agnethe Stokke; Joachim Burman; Anne Kristine Lehmann et al. (2022). Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. (ekstern lenke)
• Agnes Elisabeth Nystad; Øivind Torkildsen; Stig Wergeland (2018). Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. (ekstern lenke)
• O Torkildsen; Øivind Fredvik Torkildsen; Egil Utsi et al. (2005). Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. (ekstern lenke)
• Sonia Gavasso; Øivind Torkildsen; Tove Helene Marøy et al. (2012). Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. (ekstern lenke)
• Øivind Fredvik Torkildsen; Christian A. Vedeler; Harald Inge Nyland et al. (2006). Fc gamma R and multiple sclerosis: an overview. (ekstern lenke)
• Rune Alexander Høglund; Haakon Eduard Meyer; Hein Stigum et al. (2021). Association of body mass index in Adolescence and young Adulthood and long-term risk of multiple Sclerosis: A Population-Based Study. (ekstern lenke)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Stig Wergeland (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. (ekstern lenke)
• Øivind Torkildsen (2022). Hva vi kan lære av historien om lobotomi. (ekstern lenke)
• Anne Lise Karlsgot Hestvik; Jette Lautrup Frederiksen; Helle Hvilsted Nielsen et al. (2022). Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes. (ekstern lenke)
• Andrea Kyvik Habbestad; Johannes Sverre Willumsen; Jan Harald Aarseth et al. (2023). Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. (ekstern lenke)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2025). High-dimensional Immune Profiling Following Autologous Hematopoietic Stem Cell Transplantation in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Maria Nordheim Alme; Agnes Elisabeth Nystad; Lars Bø et al. (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. (ekstern lenke)
• Øivind Torkildsen; Stig Wergeland; Jacob Bakke et al. (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. (ekstern lenke)
• Øivind Torkildsen; Elisabeth Farbu (2005). Lars Hertervig og Carl Fredrik Hill - kreativitet og psykisk sykdom. (ekstern lenke)
• Sedina Atic Kvalvik; Ingerid Skarstein; Anne Veddeng et al. (2020). An immunocompromised woman in her twenties with abdominal pain and vaginal discharge. (ekstern lenke)
• Ingrid Anne Lie; Emma Kerklingh; Kristin Wesnes et al. (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. (ekstern lenke)
• Egil Rørvik Røsjø; Linn Hofsøy Steffensen; Lone Jørgensen et al. (2015). Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. (ekstern lenke)
• Egil Rørvik Røsjø; Jonas Christoffer Lindstrøm; Trygve Holmøy et al. (2020). Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
• Nina Grytten; Kjell-Morten Myhr; Elisabeth Gulowsen Celius et al. (2022). Cancer related mortality in multiple sclerosis. A population based cohort study. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Kjell-Morten Myhr; Søren Jacob Bakke et al. (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. (ekstern lenke)
• Ellen Skorve; Astri J. Lundervold; Øivind Torkildsen et al. (2022). Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study. (ekstern lenke)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Jacob Bakke et al. (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. (ekstern lenke)
• Erik Ingmar Hallin; Trond Trætteberg Serkland; Kjell-Morten Myhr et al. (2022). Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. (ekstern lenke)
• Jakob Rishovd Karlowicz; Mattias Klakegg; Jan Harald Aarseth et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (ekstern lenke)
• Kristin Ingeleiv Løken-Amsrud; Trygve Holmøy; Søren J. Bakke et al. (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. (ekstern lenke)
• Øivind Fredvik Torkildsen; Nina Agnethe Grytten; Kjell-Morten Myhr (2007). Immunomodulatory treatment of multiple sclerosis in Norway. (ekstern lenke)
• Øivind Torkildsen; Ralf A Linker; Jose Mm Sesmero et al. (2021). Living with secondary progressive multiple sclerosis in Europe: Perspectives of multiple stakeholders. (ekstern lenke)
• Silje Agnethe Stokke; Kjell-Morten Myhr; Trygve Holmøy et al. (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. (ekstern lenke)

Fagartikkel

• Øivind Torkildsen; Trygve Holmøy; Kjell-Morten Myhr (2018). Severe multiple sclerosis reactivation after gonadotropin treatment. (ekstern lenke)

Konferanseposter

• Tilde Rasmussen; Marton König; Åslaug Rudjord Lorentzen et al. (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis. (ekstern lenke)
• Trond Trætteberg Serkland; Erik Ingmar Hallin; Kjell-Morten Myhr et al. (2022). LC-MS/MS quantification of ocrelizumab in the treatment of multiple sclerosis. (ekstern lenke)
• Marton König; Åslaug Rudjord Lorentzen; Hilde Marie Torgauten et al. (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. (ekstern lenke)
• Marton König; Asia-Sophia Fumika Michaela Wolf; Anthony Ravussin et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (ekstern lenke)
• Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2024). Short-Term and Long-Term Impact of Autologous Haematopoietic Stem Cell Transplantation on Immune Profiles in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)

Konferanseabstrakt

• Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Anne Marita Milde et al. (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. (ekstern lenke)
• Nina Agnethe Grytten; Øivind Fredvik Torkildsen; Jan Harald Aarseth et al. (2007). Increasing prevalence of multiple sclerosis in the elderly in western Norway. (ekstern lenke)
• SS Kvistad; Kjell-Morten Myhr; Trygve Holmøy et al. (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. (ekstern lenke)
• Grytten Nina; Espen Benjaminsen; Elisabeth Gulowsen Celius et al. (2017). Cancer risk in multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Antonie Giæver Beiske et al. (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. (ekstern lenke)
• Stig Wergeland; Øivind Fredvik Torkildsen; Kjell-Morten Myhr et al. (2009). Histopathological characterisation of the cuprizone model for demyelination. (ekstern lenke)
• Christine Stansberg; S Angelska; Evert-Jan Kooi et al. (2009). Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. (ekstern lenke)

Doktorgradsavhandling

• Øivind Fredvik Torkildsen (2010). Environmental risk factors for multiple sclerosis. Results from animal and human studies on diet, vitamin D and Epstein-Barr virus. (ekstern lenke)

Konferanseforedrag

• Egil Rørvik Røsjø; Kjell-Morten Myhr; Margitta Theodora Kampman et al. (2015). Vitamin D og interferon-behandling ved multippel sklerose. (ekstern lenke)
• Trond Trætteberg Serkland; Erik Ingmar Hallin; Kjell-Morten Myhr et al. (2022). Rituximab in the treatment of multiple sclerosis: A pharmacokinetic-pharmacodynamic model. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Kristin Nielsen Varhaug; Øivind Torkildsen; Kjell-Morten Myhr et al. (2019). Neurofilament light chain as a biomarker in multiple sclerosis. (ekstern lenke)
• Shamundeeswari Anandan; Karina Maciak; Regina Breinbauer et al. (2025). Brain-derived blood biomarkers in multiple sclerosis—current trends and beyond. (ekstern lenke)
• Silje Agnethe Stokke; Stig Wergeland; Øivind Torkildsen et al. (2013). Neuromyelitis optica. (ekstern lenke)
• Kjell-Morten Myhr; Øivind Torkildsen; Peter Andreas Vold Lossius et al. (2019). B cell depletion in the treatment of multiple sclerosis. (ekstern lenke)
• Kjell-Morten Myhr; Nina Grytten; Øivind Torkildsen et al. (2015). The Norwegian Multiple Sclerosis Registry and Biobank. (ekstern lenke)
• Joost Smolders; Øivind Torkildsen; William Camu et al. (2019). An Update on Vitamin D and Disease Activity in Multiple Sclerosis. (ekstern lenke)
• Lossius Peter Andreas Vold; Jorunn Johansen; Øivind Torkildsen et al. (2012). Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation. (ekstern lenke)
• Trygve Holmøy; Rune Alexander Høglund; Zsolt Illes et al. (2020). Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. (ekstern lenke)
• Nina Grytten; Øivind Torkildsen; Kjell-Morten Myhr (2015). Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. (ekstern lenke)
• Stig Wergeland; Øivind Torkildsen; Lars Bø et al. (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. (ekstern lenke)
• Ingrid Anne Lie; Merlin M. Weeda; Rozemarijn M. Mattiesing et al. (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. (ekstern lenke)
• Karine Eid; Marte-Helene Bjørk; Nils Erik Gilhus et al. (2024). Adverse Childhood Experiences and the Risk of Multiple Sclerosis Development: A Review of Potential Mechanisms. (ekstern lenke)

Fremhevet artikkel i media

• Ingrid Anne Lie; Bjørn Blomberg; Øystein Alexander Power et al. (2018). Mann i 20-årene med svimmelhet, dobbeltsyn og perifer facialisparese. (ekstern lenke)
• Øivind Torkildsen; Brit Ellen Rød; Lars Bø et al. (2022). Amming og behandling av multippel sklerose. (ekstern lenke)

Leserbrev

• Ingrid Anne Lie; Brit Ellen Rød; Silje Agnethe Stokke et al. (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. (ekstern lenke)
• Øivind Torkildsen; Jan Harald Aarseth; Elisabeth Gulowsen Celius et al. (2014). Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. (ekstern lenke)
• Stig Wergeland; Trond Riise; Øivind Torkildsen (2018). Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. (ekstern lenke)
• Trygve Holmøy; Kristin Ingeleiv Løken-Amsrud; Margitta Theodora Kampman et al. (2014). Re: Vitamin D-how much is enough, and is more better for your Health?. (ekstern lenke)
• Gro Owren Nygaard; Hilde Marie Torgauten; Lars Skattebøl et al. (2022). Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. (ekstern lenke)
• Sreeram V Ramagopalan; Heather EC Hanwell; Gavin Giovannoni et al. (2010). Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen (2017). Re: Familieplanlegging, graviditet og amming ved multippel sklerose. (ekstern lenke)
• Øivind Torkildsen; Kjell-Morten Myhr; Pascal Brügger-Synnes et al. (2024). Antiviral therapy with tenofovir in MS. (ekstern lenke)
• Nina Grytten; Øivind Torkildsen; Kjell-Morten Myhr (2015). Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'. (ekstern lenke)

Lederartikkel

• Øivind Torkildsen (2025). Multiple Sclerosis, NMOSD, and the Risk of Autoimmune Diseases. (ekstern lenke)
• Trygve Holmøy; Øivind Torkildsen (2016). Can Vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?. (ekstern lenke)
• Thomas Skripuletz; Øivind Torkildsen (2023). Editorial: New cerebrospinal fluid research to uncover mechanisms driving neurological and psychiatric diseases, volume II. (ekstern lenke)

Vitenskapelig bokkapittel

• Kjell-Morten Myhr; Øivind Torkildsen; Lars Bø (2014). Multippel Sklerose. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin